Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) is reporting third quarter earnings results on Thursday 5th November 2020, after market close.
The consensus estimates from Thomson Reuters are loss of $ 0.2 per share.
For the full year, analysts predict revenues of $ 203.03 million, while looking forward to loss of $ 0.81 per share.
Previous Quarter Performance
Dicerna Pharmaceuticals, Inc. posted loss for the second quarter of $ 0.43 per share, from the revenue of $ 40.45 million. The quarterly revenues raised 612.15 percent compared with the same quarter last year. According to street consensus, DRNA was expected to report 2Q20 income of $ 0.10 per share from revenue of $ 62.30 million. The top line results fell short of analysts by $ 21.85 million or 35.07 percent.
Stock Performance
Shares of Dicerna Pharmaceuticals, Inc. traded up $ 1.42 or 6.53 percent on Wednesday, reaching $ 23.17 with volume of 839.90 thousand shares. Dicerna Pharmaceuticals, Inc. has traded high as $ 24.00 and has cracked $ 21.73 on the downward trend
The closing price of $ 23.17, representing a 85.11 % increase from the 52 week low of $ 11.75 and a 21.42 % decrease over the 52 week high of $ 27.68.
The company has a market capital of $ 1.73 billion and is part of the Healthcare sector and Biotechnology industry.
Conference Call
Dicerna Pharmaceuticals, Inc. will be hosting a conference call at 4:30 PM eastern time on 5th November 2020, to discuss its 3Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.dicerna.com
Dicerna Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery and development of ribonucleic acid interference (RNAi)-based pharmaceuticals. The company develops pharmaceuticals using its GalXC RNAi platform for the treatment of diseases involving the liver, including rare diseases, viral infectious diseases, chronic liver diseases, and cardiovascular diseases. Its principal development programs include DCR-PHXC for the treatment of primary hyperoxaluria; DCR-HBVS for the treatment of chronic hepatitis B virus infection; and a program for an undisclosed rare liver disease.
